{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:25:41Z","timestamp":1786955141081,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","award":["JSPS KAKENHI (Grant Number 19K07427)"],"award-info":[{"award-number":["JSPS KAKENHI (Grant Number 19K07427)"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MHLW Program for Research on Rare and Intractable Diseases","award":["JPMH23FC1042"],"award-info":[{"award-number":["JPMH23FC1042"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    Male lactotroph pituitary neuroendocrine tumors (PitNETs) are often considered more aggressive than those in women, but surgically treated cohorts are highly selected and may reflect differences in presentation and indication for surgery. We examined whether advanced clinical presentation in surgically treated lactotroph PitNETs is accompanied by distinct pathologic features. We reviewed 43 patients who underwent surgery for lactotroph PitNETs between 2018 and 2023 at a high-volume referral center. Cases were classified by surgical indication as preference for surgery\/intolerance to dopamine agonists (P\/I, n=26), resistance with hormonal symptoms (R\/H, n=10), and resistance with mass effect (R\/M, n=7). Clinical, radiologic, and pathologic parameters, including Ki-67, cytokeratin (CAM5.2), estrogen receptor, somatostatin receptor 2\/5, and O6-methylguanine-DNA methyltransferase, were compared. Postoperative endocrinological remission was assessed at the last follow-up (median: 34\u00a0mo). All tumors were prolactin-immunoreactive, confirming lactotroph differentiation. Patients in the R\/M group were older (median: 56\u00a0y), predominantly male (71.4%), and had larger tumors (median: 26\u00a0mm) with more frequent cavernous sinus invasion (Knosp grade 4, 85.7%) than those in the other groups. Long-term endocrinological remission differed significantly by indication (P\/I, 88.5%; R\/H, 80.0%; and R\/M, 0%). In contrast, Ki-67 labeling index did not differ significantly across groups (P\/I, 1.3%; R\/H, 1.5%; and R\/M, 2.6%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.598), and no clear between-group differences were identified in CAM5.2 pattern, estrogen receptor, somatostatin receptor 2\/5, or O6-methylguanine-DNA methyltransferase status. These findings suggest that the clinically most advanced surgical cases are not matched by distinct pathologic differences in the markers assessed and that the apparent aggressiveness of male-predominant mass-effect cases should not be interpreted solely as reflecting intrinsically aggressive tumor biology.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002577","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:00:10Z","timestamp":1783594810000},"page":"1097-1105","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathologic Analysis of 43 Surgically Resected Lactotroph Pituitary Neuroendocrine Tumors Stratified by Surgical Indication"],"prefix":"10.1097","volume":"50","author":[{"given":"Noriaki","family":"Tanabe","sequence":"first","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Human Pathology, Institute of Science"},{"name":"Department of Neurosurgery, National Defense Medical College, Saitama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kasuga","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shiramizu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Tateno","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terushige","family":"Toyooka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, National Defense Medical College, Saitama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Institute of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tokyo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tokyo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hypothalamic and Pituitary Center, Moriyama Neurological Center Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-019-00997-1","article-title":"Pathology of prolactinomas: any predictive value?","volume":"23","author":"Lopes","year":"2020","journal-title":"Pituitary"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","article-title":"Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis","volume":"24","author":"Yagnik","year":"2021","journal-title":"Pituitary"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"R8-20260817","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4065\/73.11.1046","article-title":"Prolactinomas in male and female patients: a comparative clinicopathologic study","volume":"73","author":"Calle-Rodrigue","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"R10-20260817","first-page":"152","article-title":"Gender-related differences in prolactinomas. A clinicopathologic study","volume":"26","author":"Schaller","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12020-019-01962-5","article-title":"Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years","volume":"65","author":"Shimon","year":"2019","journal-title":"Endocrine"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0090-3019(03)00012-0","article-title":"Growth potential of prolactinomas in men: is it really different from women?","volume":"59","author":"Nishioka","year":"2003","journal-title":"Surg Neurol"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1078\/0344-0338-00117","article-title":"Pituitary tumors in the elderly","volume":"197","author":"Kurosaki","year":"2001","journal-title":"Pathol Res Pract"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/eje.1.02107","article-title":"Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data","volume":"154","author":"Buurman","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"R18-20260817","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-021-01192-x","article-title":"Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay","volume":"25","author":"Ishida","year":"2022","journal-title":"Pituitary"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","article-title":"Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance","volume":"147","author":"Delgrange","year":"2005","journal-title":"Acta Neurochir (Wien)"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00234-002-0774-2","article-title":"Gender-related differences in prolactin secretion in pituitary prolactinomas","volume":"44","author":"Nishioka","year":"2002","journal-title":"Neuroradiology"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:00:19Z","timestamp":1786953619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002577"}},"subtitle":["A Pathologic Reappraisal of Apparent Male Aggressiveness"],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002577","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}